COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

A Phase I Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Protocol No
FATE-FT576-101-MM
Principal Investigator
Binod Dhakal
Phase
I
Summary
This project is being done to test the safety of FT576 at different doses and schedules and to understand the way your body processes and responds to FT576. The study will also find out what effects FT576, when given alone or in combination with a monoclonal antibody, may have on you and your cancer.
Description
Study of FT576 as Monotherapy and Combination with Daratumumab in Subjects with r/r MM
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL